Overview

Study of Megestrol Acetate in Grade 2 Endometrioid Endometrial Cancer

Status:
Not yet recruiting
Trial end date:
2024-09-01
Target enrollment:
Participant gender:
Summary
This is a single centre, single arm, open label, preoperative window of opportunity study. Grade 2 endometrioid endometrial carcinoma patients awaiting surgery will be prospectively recruited to receive a pre-operative progestin therapy course. Therapy response will be histologically evaluated and correlated with clinical and molecular data by comparison of responders vs. non-responders pre- and post-treatment tumor samples.
Phase:
Phase 1
Details
Lead Sponsor:
Sunnybrook Health Sciences Centre
Collaborator:
Ontario Institute for Cancer Research
Treatments:
Megestrol
Megestrol Acetate